Radioactive tracers aim to spot Parkinson's in the brain
NCT ID NCT06949670
First seen Feb 01, 2026 · Last updated Jun 20, 2026 · Updated 16 times
Summary
This study is testing three new radioactive tracers that light up alpha-synuclein clumps in the brain during PET/CT scans. Researchers want to see if these scans can accurately diagnose Parkinson's disease and related disorders. 500 adults with suspected or confirmed Parkinson's will receive one injection and undergo imaging. The goal is to improve diagnosis, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
RECRUITINGHefei, Anhui, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Tianjin Municipality, 300052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-FIAT-2, 18F-C05-05, 18F-SPAL-T-06 (radioactive tracers for PET/CT imaging)
What this could lead to
If successful, this could lead to a more accurate way to diagnose Parkinson's disease and related conditions using brain imaging.
What could go wrong
This is an early diagnostic study, not a treatment. The tracers may not reliably detect alpha-synuclein in all patients, and results may not change clinical care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.